---
title: BSEP Inhibition Webinar Registration
description: "Register for our webinar \"How And When To Evaluate BSEP Inhibition To Help Reduce Human DILI Risk: ITC Recommendations” to hear ITC guidance on assessing BSEP inhibition during the drug development process in order to reduce and manage DILI risk."
image: http://info.bioivt.com/hubfs/BioIVT-logo-min.jpg
---

*Questions? We’re here to help:*

[+1 516-483-1196](tel:+1%20516-483-1196) or [+44 1444 707333](tel:+44%201444%20707333)

[Contact Us](https://www.bioivt.com/about/contact-us)

[![BioIVT-Logo-Tag-New](https://info.bioivt.com/hubfs/BioIVT-Logo-Tag-New.png)](https://bioivt.com)

- [BioIVT.com](https://bioivt.com/)

Search

[View My Quote](https://www.bioivt.com/?showQuoteOverlay=true)

# Register for our live webinar *How and When to Evaluate BSEP Inhibition to Help Reduce Human DILI Risk: ITC Recommendations *

**Date:** Thursday, July 18th, 2019  
**Time:** 11 am ET, 8 am PT, 4 pm GMT

Inhibition of the Bile Salt Export Pump (BSEP), which is a membrane transport protein present in the liver, is now considered to be one of several important mechanisms by which drug induced liver injury (DILI) may arise in humans. Recently the International Transporter Consortium (ITC) issued pragmatic recommendations on experimental methods that can be used to assess BSEP inhibition during drug development, and thereby to reduce and manage DILI risk.

Attend our webinar to hear Dr. Gerry Kenna’s presentation, “**How And When To Evaluate BSEP Inhibition To Help Reduce Human DILI Risk: ITC Recommendations”**. Dr. Kenna will discuss the ITC guidance on assessing BSEP inhibition during the drug development process in order to reduce and manage DILI risk.

- Adapt *in vitro* liver models for high-throughput drug discovery
- Drug discovery limitations using hepatic models
- Use of high-content imaging in research

**SPEAKER**  
![Dr Kenna](https://info.bioivt.com/hs-fs/hubfs/Dr%20Kenna.jpg?width=204&name=Dr%20Kenna.jpg)

**Gerry Kenna, Ph.D. FBTS  
Pharmaceutical Director, Safer Medicines Trust**

 Gerry Kenna is Pharmaceutical Director of [Safer Medicines Trust](https://safermedicines.org/), a drug safety consultant and Vice President of the Board of Trustees of the [Evidence Based Toxicology Collaboration](http://www.ebtox.org/). His work is focused on developing and implementing novel, human biology-based methods that can improve human drug safety evaluation. Previously he was a toxicologist in the pharmaceutical and agrochemical industries for 15 years, having led academic research teams that explored mechanisms underlying serious human adverse drug reactions for 19 years. Dr. Kenna received B.Sc. and Ph.D. degrees in biochemistry from the Universities of Leeds and London, respectively.

### Register Now

Copyright © 2026 BioIVT. All Rights Reserved. [Contact Us](https://www.bioivt.com/about/contact-us/).